A recent study found that in addition to the COL1A1‐PDGFβ fusion gene, a novel fusion gene of SLC2A5‐BTBD7 is also present in DFSP, which may serve as a new therapeutic target [11]. The gene discussed is SLC2A5; the disease is dermatofibrosarcoma protuberans.